StockData
CRISPR Therapeutics AG logo

CRISPR Therapeutics AG (CRSP) stock

CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$40.15−0.22 (-0.54%)

Close on Nov 17, 2026Market cap $3.88BP/E –Yield –

CRISPR Therapeutics total assets

Total assets on the balance sheet at the end of each period.

CRISPR Therapeutics's total assets was $2.65B at Jun 30, 2026. For fiscal 2025 it was $2.27B, up 1.0% from the year before. Over ten years it grew 30.4% a year on average. The highest annual figure on record is $2.75B in fiscal 2021.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.27B+1.0%
FY2024Dec 31, 2024$2.24B+0.6%
FY2023Dec 31, 2023$2.23B-0.6%
FY2022Dec 31, 2022$2.24B-18.5%
FY2021Dec 31, 2021$2.75B+50.5%
FY2020Dec 31, 2020$1.83B+71.4%
FY2019Dec 31, 2019$1.07B+118.1%
FY2018Dec 31, 2018$489.02M+80.2%
FY2017Dec 31, 2017$271.35M-21.3%
FY2016Dec 31, 2016$344.96M+116.4%
FY2015Dec 31, 2015$159.42M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.65B+30.6%
Q1 FY2026Mar 31, 2026$2.73B+25.8%
Q4 FY2025Dec 31, 2025$2.27B+1.0%
Q3 FY2025Sep 30, 2025$2.25B-0.5%
Q2 FY2025Jun 30, 2025$2.03B-13.3%
Q1 FY2025Mar 31, 2025$2.17B-11.2%
Q4 FY2024Dec 31, 2024$2.24B+0.6%
Q3 FY2024Sep 30, 2024$2.26B+8.1%
Q2 FY2024Jun 30, 2024$2.34B+6.5%
Q1 FY2024Mar 31, 2024$2.44B+8.7%
Q4 FY2023Dec 31, 2023$2.23B-0.6%
Q3 FY2023Sep 30, 2023$2.09B-11.3%
Q2 FY2023Jun 30, 2023$2.20B-10.8%
Q1 FY2023Mar 31, 2023$2.24B-13.9%
Q4 FY2022Dec 31, 2022$2.24B-18.5%
Q3 FY2022Sep 30, 2022$2.35B-16.6%
Q2 FY2022Jun 30, 2022$2.46B-15.0%
Q1 FY2022Mar 31, 2022$2.61B+33.1%
Q4 FY2021Dec 31, 2021$2.75B+50.5%
Q3 FY2021Sep 30, 2021$2.82B+90.0%
Q2 FY2021Jun 30, 2021$2.90B+177.1%
Q1 FY2021Mar 31, 2021$1.96B+94.4%
Q4 FY2020Dec 31, 2020$1.83B+71.4%
Q3 FY2020Sep 30, 2020$1.49B+106.1%
Q2 FY2020Jun 30, 2020$1.05B+111.7%
Q1 FY2020Mar 31, 2020$1.01B+102.3%
Q4 FY2019Dec 31, 2019$1.07B+118.1%
Q3 FY2019Sep 30, 2019$720.59M+38.9%
Q2 FY2019Jun 30, 2019$494.25M+40.0%
Q1 FY2019Mar 31, 2019$497.87M+33.0%
Q4 FY2018Dec 31, 2018$489.02M+80.2%
Q3 FY2018Sep 30, 2018$518.90M+83.8%
Q2 FY2018Jun 30, 2018$353.13M+15.8%
Q1 FY2018Mar 31, 2018$374.45M+16.2%
Q4 FY2017Dec 31, 2017$271.35M-21.3%
Q3 FY2017Sep 30, 2017$282.32M+1.3%
Q2 FY2017Jun 30, 2017$304.98M–
Q1 FY2017Mar 31, 2017$322.35M–
Q4 FY2016Dec 31, 2016$344.96M–
Q3 FY2016Sep 30, 2016$278.65M–

More CRISPR Therapeutics figures

See a number that looks wrong?